We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Optibiotix Health Plc | LSE:OPTI | London | Ordinary Share | GB00BP0RTP38 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 17.75 | 17.50 | 18.00 | 17.75 | 17.75 | 17.75 | 57,000 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Noncomml Resh Organizations | 457k | 2.59M | 0.0284 | 6.25 | 16.19M |
Date | Subject | Author | Discuss |
---|---|---|---|
18/1/2017 19:58 | I think it jumped over 500% at one point Neft (while I looked on jealously)... and if you had been quick with the trigger finger people could've actually jumped on that rocket first thing as the MMs only opened up a little above yesterday's close. That would certainly be Awesome if we saw a rise like that from OPTI on a great bit of news.... but I don't think we'll see that sort of jump from our current level (FItbug were pretty much at an all time low and so had a long way to go). CheersSienna | siennadelekat21 | |
18/1/2017 19:34 | 3,000% Don't think so neft Ended up Approx 370% | judijudi | |
18/1/2017 19:26 | o/t did you see that rise in FITBUG (FITB) today, over 3,000%, after an order win with,i think, TARA, is that the same as opti might be in with, or am i completely wrong ? | neftanikoff | |
18/1/2017 19:09 | "Optibiotix: Broadening formation points towards 90p By Zak Mir 18 January 2017 Optibiotix (LON:OPTI) has been one of those rare beasts: a reliable small cap company prospect. Here the shares have gone up, and largely stayed up. As luck would have it, today I bumped into the CEO of Optibiotix, Stephen O’Hara. The company is one I have followed from the word go, and its continued progress is most welcome. The particular areas this company is tackling are among the most difficult to address or indeed treat. I am of course referring to obesity, high cholesterol, diabetes and skin care. What can be seen on the daily chart in the journey from the autumn of 2015 is that we were treated to a break above the 40p region, with there being a brief near vertical move through 100p for November. Essentially, what can be deduced about the price action since then is that we have essentially been in consolidation mode within a broad triangle with its support line projection running towards 60p. This implies that while above the floor of this formation on a weekly close basis, we are very much expecting the shares to deliver a decent new leg to the upside, and not just a temporary blip. Evidence for this would come from a weekly close above the 200 day moving average at 73.5p. As long as you wait on a clearance of the 200 day line, the upside here at Optibiotix should be 105p plus at the top of the triangle formation." | someuwin | |
18/1/2017 19:04 | I can be :-) | elrico | |
18/1/2017 18:55 | Life sciences group OptiBiotix Health plc (LON:OPTI) is bringing on board an experienced sales and marketing director to help create new revenue streams for OptiBiotix’s pipeline of products. Christina Wood will join the team in due course subject to the completion of the normal regulatory due diligence, Opti said. She has been brought in to help take OptiBiotix’s products, including its patented SlimBiome weight loss products, into overseas markets. Wood has more than 20 years’ sales experience in the food, nutrition and nutraceuticals industry and has struck deals with likes of Nestlé, Danone and Heinz in the past in her role as chief executive and owner of ingredients supplier Confoco. Most recently, she was the director of sales and marketing at UK food supplier John Morley where she was responsible for key accounts including Tesco PLC (LON:TSCO) and J Sainsbury plc (LON:SBRY). “Christina's experience of building sales in her own business by developing relationships with food ingredient manufacturers and major retailers brings new elements of operational, commercial and industry expertise to OptiBiotix,” said chief executive Stephen O’Hara in this morning’s statement. Speaking exclusively to Proactive, he added: “You can see we’re transitioning now from a company that was very much focused on developing products to a company that is now commercialising their products.” Shares were up 5.5%, or 3.8p, to 72.3p. | elrico | |
18/1/2017 18:25 | Funny :) Have you never read any of Diamonds predictions before? I guess not!! | judijudi | |
18/1/2017 18:13 | JJ - lay off diamond that was not called for, AND IF we get something interesting on or shortly following the 5th, an apology might be in order. We know the Bio conference is the last part of the previous week, so perhaps it is the publication of one of the Scientific Journals that is about to appear. But - who knows - Best wishes - Mike | spike_1 | |
18/1/2017 18:12 | 90p - apparently! Optibiotix (LON:OPTI) has been one of those rare beasts: a reliable small cap company prospect. Here the shares have gone up, and largely stayed up. As luck would have it, today I bumped into the CEO of Optibiotix, Stephen O’Hara. The company is one I have followed from the word go, and its continued progress is most welcome. The particular areas this company is tackling are among the most difficult to address or indeed treat. I am of course referring to obesity, high cholesterol, diabetes and skin care. What can be seen on the daily chart in the journey from the autumn of 2015 is that we were treated to a break above the 40p region, with there being a brief near vertical move through 100p for November. Essentially, what can be deduced about the price action since then is that we have essentially been in consolidation mode within a broad triangle with its support line projection running towards 60p. This implies that while above the floor of this formation on a weekly close basis, we are very much expecting the shares to deliver a decent new leg to the upside, and not just a temporary blip. Evidence for this would come from a weekly close above the 200 day moving average at 73.5p. As long as you wait on a clearance of the 200 day line, the upside here at Optibiotix should be 105p plus at the top of the triangle formation opti chart | elrico | |
18/1/2017 17:02 | Confirmed Tool! | judijudi | |
18/1/2017 16:50 | My fault, he said week commencing the 5th, my apologies | diamond fibre | |
18/1/2017 16:44 | [...] Speaking exclusively to Proactive, he (SOH) added: “You can see we’re transitioning now from a company that was very much focused on developing products to a company that is now commercialising their products.” | parob | |
18/1/2017 16:29 | Diamond what a Tool!! :) | judijudi | |
18/1/2017 15:54 | or going to church to pray for a good deal? ;-) | fozdad | |
18/1/2017 15:53 | Yeah best look up your dates diamond before posting,unless of course SOH is taking the staff out for a Sunday picnic. | scotty1 | |
18/1/2017 15:35 | ...Seeing as the 5th of Feb is a Sunday I won't hold him to it. | someuwin | |
18/1/2017 15:26 | My contact reckons Febuary is going to be a great month for us, he did mention the 5th of Feb but he said not to hold him to that date. | diamond fibre | |
18/1/2017 14:11 | The very point I made earlier with fewer words (for mazzstar's benefit)..."fatted calf" :-) | elrico | |
18/1/2017 13:40 | Great additions to the team recently. Today's unexpected announcement most importantly confirms that opti is now transitioning from the development phase to the 'patiently' awaited commercial phase. The fact they have appointed a second commercial figure spells out to me significant revenues are not far away. It also reinforces soh comments regarding discussions with multiple partners. The calibre of these appointments demonstrates intent for strong global revenue growth in the near future. In order to attract such figures to such an early stage company proves this is now turning from potential to reality. Slimbiome and lpldl can now be pushed through a newly established network of valuable experience and contacts. As well as a pipeline of higher spec technology that will demand even higher returns in the future. | riskybusiness1 | |
18/1/2017 12:45 | Just ticked up again....Starting to look v.good here, 2017 could be our year. | woodaldo | |
18/1/2017 12:20 | A post by AL75 on the lse bb just now:"Yesterday the price of OPTI perfectly dropped to 66p, a level exactly on its previous downtrend line. It then moved up to close at 69p (i.e. resistance becomes support). The candlestick pattern from the last 3 days is also a bullish reversal which includes a hammer and is similar to a morning star pattern. With a rising MACD and RSI all the indicators and patterns together are signalling "buy"." | parob | |
18/1/2017 11:58 | The big money is probably in the contracts that the two new arrivals will sign!! | bobdown2 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions